Hepatology
Feature
Direct-acting antivirals tied to better outcomes in chronic Hep C
Researchers saw a significant reduction in all-cause mortality over a decade with direct-acting antivirals compared with no treatment.
Conference Coverage
A bold national plan to eliminate HCV by 2050
“We don’t get to use the ‘eliminate’ word all that often with a disease that’s taking thousands or tens of thousands – or worldwide, hundreds of...
Commentary
How a cheap liver drug may be the key to preventing COVID
The authors of a paper appearing in Nature give us multiple, complementary lines of evidence.
Conference Coverage
Poor NAFLD outcomes with increased VCTE-measured liver stiffness
The findings show that “progression to LSM-defined cirrhosis by VCTE is strongly associated with poor clinical outcomes.”
Conference Coverage
Midodrine may be comparable to albumin for PICD prevention in ACLF
Given the small size of the open-label study, with only 25 patients in each arm, the results should be considered as proof of concept and need to...
Conference Coverage
Bepirovirsen: Is a ‘functional cure’ for HBV on the horizon?
“Bepirovirsen is just one RNA-based HBV therapy now being pursued. Several other antisense RNAs as well as the more malleable small interfering...
Conference Coverage
Steroids and G-CSF improve 90-day survival in severe alcoholic hepatitis
In addition to its superior results on the primary endpoint of 90-day survival, combination therapy was associated with significantly better...
Conference Coverage
Liver disease-related deaths rise during pandemic
“The increasing trend in mortality rates for ALD and NAFLD has been quite alarming, with disparities in age, race, and ethnicity.”
Conference Coverage
World falls short on HBV, HCV elimination targets
“As countries progress toward eliminating hepatitis B and C, we really need to do more to expand political will and financing of national...
Conference Coverage
NAFLD patients with diabetes have higher fibrosis progression rate
Patients with type 2 diabetes had about a 2-year faster progression to fibrosis.
Conference Coverage
Resmetirom reduces liver, CV risk factors in NASH with cirrhosis
“I do think it could be one of the drugs that really improves outcomes for patients with NASH.”